文献速递妇科产科

肥胖与帕博利珠单抗治疗的微卫星高度不稳定子宫内膜癌无进展生存期改善相关

Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
PubMed 文献 · Gynecol Oncol · 2023-12-12

这项回顾性单中心研究纳入44例2017至2021年接受帕博利珠单抗单药治疗的晚期或复发错配修复缺陷(MMRd)或微卫星高度不稳定(MSI-H)子宫内膜腺癌患者,中位BMI为32.9。肥胖(BMI≥30)与疾病控制率升高(OR 4.03,95%CI 1.09,28)和无进展生存期改善(p=0.03)相关,总生存期无显著差异(p=0.5)。

要点

  • 44例晚期或复发MMRd/MSI-H子宫内膜腺癌患者接受帕博利珠单抗单药治疗,中位随访33个月。
  • 肥胖(BMI≥30)与疾病控制率升高相关(OR 4.03,95%CI 1.09,28)。
  • 肥胖(BMI≥30)患者无进展生存期显著延长(p=0.03),总生存期无显著差异(p=0.5)。

核心结论

  • 在这项回顾性研究中,肥胖与帕博利珠单抗治疗的复发或晚期MMRd/MSI-H子宫内膜腺癌患者疾病控制率升高和无进展生存期改善相关。

研究设计与样本

  • 回顾性单中心研究,纳入2017至2021年在本机构接受帕博利珠单抗单药治疗的复发或晚期MMRd或MSI-H子宫内膜腺癌女性患者44例。

主要发现

  • 44例患者中位BMI为32.9(范围18.5-51.8),中位帕博利珠单抗周期数为11.5(范围2-37),中位随访33个月(范围5-61)。
  • 总体缓解率为63.6%,疾病稳定率为75%。
  • 按肥胖状态(BMI≥30)分层,BMI<30患者疾病控制率为59.8%,BMI≥30患者为85.2%(p=0.05)。
  • 多变量分析中,肥胖与疾病控制率升高相关(OR 4.03,95%CI 1.09,28),既往吸烟与疾病控制率降低相关(OR 0.18,95%CI 0.03,0.85)。
  • BMI≥30患者无进展生存期显著延长(p=0.03),但总生存期相似(p=0.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the clinical predictors of response rate, progression-free survival (PFS), and overall survival (OS) to pembrolizumab in advanced or recurrent, mismatch repair deficient (MMRd) or Microsatellite Instability-High (MSI-H) endometrial adenocarcinomas. METHODS: A retrospective, single institution study was conducted among women with recurrent or advanced MMRd or MSI-H endometrial adenocarcinomas treated with single-agent pembrolizumab at our institution from 2017 to 2021. Logistic regression was used for univariable and multivariable analyses. PFS and OS were estimated using the methods of Kaplan and Meier and modeled via Cox proportional hazards regression. Log-rank test was used for intergroup comparisons based on body mass index (BMI). RESULTS: Among the 44 patients included in the analysis, the median BMI was 32.9 (range 18.5-51.8). Median cycles of pembrolizumab given was 11.5 (range 2-37). Median follow-up was 33 months (range 5-61) with a response rate of 63.6% and stable disease rate of 75%. When stratified by obesity status (BMI≥30), disease control rate was 59.8% in patients with a BMI < 30 and 85.2% in patients with a BMI≥30 patients (p = 0.05). On multivariable analysis, obesity was associated with increased rate of disease control (OR 4.03, 95%CI 1.09, 28) while prior smoking was associated with decreased rate of disease control (OR 0.18, 95%CI 0.03, 0.85). PFS was significantly increased among patients with a BMI≥30 (p = 0.03) but OS was similar (p = 0.5). CONCLUSION: In this retrospective study, obesity is associated with increased rates of disease control and improved PFS in patients treated with pembrolizumab for recurrent or advanced MMRd/MSI-H endometrial adenocarcinomas.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bernard L, How JA, Patel S, et al. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecol Oncol. 2023. PMID: 38091773. doi:10.1016/j.ygyno.2023.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。